Endothelin type A receptor blockade increases renoprotection in congestive heart failure combined with chronic kidney disease: studies in 5/6 nephrectomized rats with aorto-caval fistula

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F23%3A00083626" target="_blank" >RIV/00023001:_____/23:00083626 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/67985823:_____/23:00568956 RIV/00216208:11130/23:10452798 RIV/61989592:15110/23:73619154 RIV/00098892:_____/23:10158364 RIV/00064203:_____/23:10452798

Výsledek na webu

<a href="https://reader.elsevier.com/reader/sd/pii/S0753332222015463?token=5CCD3BF1D968FED00BE1B886260DEC141309A29A5DFA3A23EBCFB4309E9548E79A30532D0BFAFAFD99D0BEF026B531F8&originRegion=eu-west-1&originCreation=20230221103007" target="_blank" >https://reader.elsevier.com/reader/sd/pii/S0753332222015463?token=5CCD3BF1D968FED00BE1B886260DEC141309A29A5DFA3A23EBCFB4309E9548E79A30532D0BFAFAFD99D0BEF026B531F8&originRegion=eu-west-1&originCreation=20230221103007</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.biopha.2022.114157" target="_blank" >10.1016/j.biopha.2022.114157</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Endothelin type A receptor blockade increases renoprotection in congestive heart failure combined with chronic kidney disease: studies in 5/6 nephrectomized rats with aorto-caval fistula

Popis výsledku v původním jazyce

Background: Association of congestive heart failure (CHF) and chronic kidney disease (CKD) worsens the patient&apos;s prognosis and results in poor survival rate. The aim of this study was to examine if addition of endothelin type A (ETA) receptor antagonist to the angiotensin-converting enzyme inhibitor (ACEi) will bring additional beneficial effects in experimental rats.Methods: CKD was induced by 5/6 renal mass reduction (5/6 NX) and CHF was elicited by volume overload achieved by creation of aorto-caval fistula (ACF). The follow-up was 24 weeks after the first intervention (5/6 NX). The treatment regimens were initiated 6 weeks after 5/6 NX and 2 weeks after ACF creation.Results: The final survival in untreated group was 15%. The treatment with ETA receptor antagonist alone or ACEi alone and the combined treatment improved the survival rate to 64%, 71% and 75%, respectively, however, the difference between the combination and either single treatment regimen was not significant. The combined treatment exerted best renoprotection, causing additional reduction in albuminuria and reducing renal glomerular and tubulointerstitial injury as compared with ACE inhibition alone.Conclusions: Our results show that treatment with ETA receptor antagonist attenuates the CKD-and CHF-related mortality, and addition of ETA receptor antagonist to the standard blockade of RAS by ACEi exhibits additional renoprotective actions.

Název v anglickém jazyce

Endothelin type A receptor blockade increases renoprotection in congestive heart failure combined with chronic kidney disease: studies in 5/6 nephrectomized rats with aorto-caval fistula

Popis výsledku anglicky

Background: Association of congestive heart failure (CHF) and chronic kidney disease (CKD) worsens the patient&apos;s prognosis and results in poor survival rate. The aim of this study was to examine if addition of endothelin type A (ETA) receptor antagonist to the angiotensin-converting enzyme inhibitor (ACEi) will bring additional beneficial effects in experimental rats.Methods: CKD was induced by 5/6 renal mass reduction (5/6 NX) and CHF was elicited by volume overload achieved by creation of aorto-caval fistula (ACF). The follow-up was 24 weeks after the first intervention (5/6 NX). The treatment regimens were initiated 6 weeks after 5/6 NX and 2 weeks after ACF creation.Results: The final survival in untreated group was 15%. The treatment with ETA receptor antagonist alone or ACEi alone and the combined treatment improved the survival rate to 64%, 71% and 75%, respectively, however, the difference between the combination and either single treatment regimen was not significant. The combined treatment exerted best renoprotection, causing additional reduction in albuminuria and reducing renal glomerular and tubulointerstitial injury as compared with ACE inhibition alone.Conclusions: Our results show that treatment with ETA receptor antagonist attenuates the CKD-and CHF-related mortality, and addition of ETA receptor antagonist to the standard blockade of RAS by ACEi exhibits additional renoprotective actions.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Biomedicine and pharmacotherapy

ISSN

0753-3322

e-ISSN

1950-6007

Svazek periodika

158

Číslo periodika v rámci svazku

February

Stát vydavatele periodika

FR - Francouzská republika

Počet stran výsledku

11

Strana od-do

"art. no. 114157"

Kód UT WoS článku

000916209900001

EID výsledku v databázi Scopus

2-s2.0-85145296028